Buscail L, Estève J P, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A M, Bell G I, Schally A V, Vaysse N, Susini C
Institut National de la Santé et de la Recherche Médicale U151, Institut Louis Bugnard, CHU Rangueil, Toulouse, France.
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4. doi: 10.1073/pnas.92.5.1580.
Effects of the stable somatostatin analogue RC-160 on cell proliferation, tyrosine phosphatase activity, and intracellular calcium concentration were investigated in CHO cells expressing the five somatostatin receptor subtypes SSTR1 to -5. Binding experiments were performed on crude membranes by using [125I-labeled Tyr11] somatostatin-14; RC-160 exhibited moderate-to-high affinities for SSTR2, -3, and -5 (IC50, 0.17, 0.1 and 21 nM, respectively) and low affinity for SSTR1 and -4 (IC50, 200 and 620 nM, respectively). Cell proliferation was induced in CHO cells by 10% (vol/vol) fetal calf serum, 1 microM insulin, or 0.1 microM cholecystokinin (CCK)-8; RC-160 inhibited serum-induced proliferation of CHO cells expressing SSTR2 and SSTR5 (EC50, 53 and 150 pM, respectively) but had no effect on growth of cells expressing SSTR1, -3, or -4. In SSTR2-expressing cells, orthovanadate suppressed the growth inhibitory effect of RC-160. This analogue inhibited insulin-induced proliferation and rapidly stimulated the activity of a tyrosine phosphatase in only this cellular clone. This latter effect was observed at doses of RC-160 (EC50, 4.6 pM) similar to those required to inhibit growth (EC50, 53 pM) and binding to the receptor (IC50, 170 pM), implicating tyrosine phosphatase as a transducer of the growth inhibition signal in SSTR2-expressing cells. In SSTR5-expressing cells, the phosphatase pathway was not involved in the inhibitory effect of RC-160 on cell growth, since this action was not influenced by tyrosine and serine/threonine phosphatase inhibitors. In addition, in SSTR5-expressing cells, RC-160 inhibited CCK-stimulated intracellular calcium mobilization at doses (EC50, 0.35 nM) similar to those necessary to inhibit somatostatin-14 binding (IC50, 21 nM) and CCK-induced cell proliferation (EC50, 1.1 nM). This suggests that the inositol phospholipid/calcium pathway could be involved in the antiproliferative effect of RC-160 mediated by SSTR5 in these cells. RC-160 had no effect on the basal or carbachol-stimulated calcium concentration in cells expressing SSTR1 to -4. Thus, we conclude that SSTR2 and SSTR5 bind RC-160 with high affinity and mediate the RC-160-induced inhibition of cell growth by distinct mechanisms.
在表达5种生长抑素受体亚型SSTR1至SSTR5的CHO细胞中,研究了稳定的生长抑素类似物RC - 160对细胞增殖、酪氨酸磷酸酶活性和细胞内钙浓度的影响。通过使用[125I标记的Tyr11]生长抑素-14对粗制细胞膜进行结合实验;RC - 160对SSTR2、-3和-5表现出中等到高亲和力(IC50分别为0.17、0.1和21 nM),对SSTR1和-4表现出低亲和力(IC50分别为200和620 nM)。10%(体积/体积)胎牛血清、1 μM胰岛素或0.1 μM胆囊收缩素(CCK)-8可诱导CHO细胞增殖;RC - 160抑制表达SSTR2和SSTR5的CHO细胞的血清诱导增殖(EC50分别为53和150 pM),但对表达SSTR1、-3或-4的细胞生长无影响。在表达SSTR2的细胞中,原钒酸盐抑制了RC - 160的生长抑制作用。该类似物仅在该细胞克隆中抑制胰岛素诱导的增殖并迅速刺激酪氨酸磷酸酶的活性。在与抑制生长(EC50为53 pM)和与受体结合(IC50为170 pM)所需剂量相似的RC - 160剂量(EC50为4.6 pM)下观察到了后一种效应,这表明酪氨酸磷酸酶是表达SSTR2的细胞中生长抑制信号的转导分子。在表达SSTR5的细胞中,磷酸酶途径不参与RC - 160对细胞生长的抑制作用,因为该作用不受酪氨酸和丝氨酸/苏氨酸磷酸酶抑制剂的影响。此外,在表达SSTR5的细胞中,RC - 160在与抑制生长抑素-14结合(IC50为21 nM)和CCK诱导的细胞增殖(EC50为1.1 nM)所需剂量相似的剂量(EC50为0.35 nM)下抑制CCK刺激的细胞内钙动员。这表明肌醇磷脂/钙途径可能参与了RC - 160由SSTR5介导的在这些细胞中的抗增殖作用。RC - 160对表达SSTR1至SSTR4的细胞的基础或卡巴胆碱刺激的钙浓度无影响。因此,我们得出结论,SSTR2和SSTR5以高亲和力结合RC - 160,并通过不同机制介导RC - 160诱导的细胞生长抑制。